Immune intervention therapy in type 1 diabetes: Safety first

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 4, 2013, Pages 263-265

  Roep, Bart O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; PLACEBO; RAPAMYCIN; RITUXIMAB;

B LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; EOSINOPHIL COUNT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SAFETY; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; VASCULITIS; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNOLOGY; MALE;

DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INTERLEUKIN-2; MALE;

EID: 84887625697     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70124-4     Document Type: Letter

References (10)

1. Roep BO, Buckner J, Sawcer S, Toes R, Zipp F The problems and promises of research into human immunology and autoimmune disease. Nat Med 2012, 18:48-53.
2. von Herrath M, Peakman M, Roep B Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol 2013, 172:186-202.
3. Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012, 61:2340-2348.
4. Hartemann A, Bensimon G, Payan CA, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013, published online Oct 8. http://dx.doi.org/10.1016/S2213-8587(13)70113-X.
5. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nature Genet 2009, 41:703-707.
6. Buckner JH Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nature Rev Immunology 2010, 10:849-859.
7. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
8. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011, 365:2067-2077.
9. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011, 365:2055-2066.
10. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152.